Business Wire

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 1 and affects nearly 7.7 million people in the U.S. 2 ...
Nasdaq

FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatment

(RTTNews) - The U.S. Food and Drug Administration approved Eli Lilly and Co.'s (LLY) Mounjaro or tirzepatide injection for the treatment of adults with type 2 diabetes. Mounjaro represents the first ...
Nasdaq

FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus ...
Bloomberg L.P.

Novo in Supply Deal With Ypsomed for Auto-Injector Pens

Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors. Ypsomed is ...